BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 32162869)

  • 1. Association of CXCR4 Expression and Clinical Outcome in Different Subsets of De Novo Acute Myeloid Leukemia Patients.
    Rady AS; Badawy RH; Gamal BME; Darwish AD; Aziz RSA; Gammal ME; Goweda RA
    Clin Lab; 2020 Mar; 66(3):. PubMed ID: 32162869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between CXC chemokine receptor 4 expression and prognostic significance in acute myeloid leukemia.
    Cao T; Ye Y; Liao H; Shuai X; Jin Y; Su J; Zheng Q
    Medicine (Baltimore); 2019 Jun; 98(23):e15948. PubMed ID: 31169718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of CXCR4 in acute myeloid leukemia.
    Ahn JY; Seo K; Weinberg OK; Arber DA
    Appl Immunohistochem Mol Morphol; 2013 Jan; 21(1):79-84. PubMed ID: 22914607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of polymorphisms of stromal-derived factor-1 and CXC receptor 4 in acute myeloid leukemia and leukemia cell dissemination.
    Zheng Q; Shuai X; Ye Y; Jin Y; Jiang N; Chen X; Su J
    Gene; 2016 Aug; 588(2):103-8. PubMed ID: 27154815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of CXCR4 in the pathogenesis of acute myeloid leukemia.
    Peled A; Tavor S
    Theranostics; 2013; 3(1):34-9. PubMed ID: 23382784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of SDF-1 Gene Polymorphism with Increased Risk of Acute Myeloid Leukemia Patients.
    Aladle DAAM; Ghannam MA; El-Ashwah S; Ghobrial FEI; Mortada MI
    Asian Pac J Cancer Prev; 2021 Apr; 22(4):1035-1043. PubMed ID: 33906294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stromal-derived factor-1 deficiency in the bone marrow of acute myeloid leukemia.
    Ge J; Hou R; Liu Q; Zhu R; Liu K
    Int J Hematol; 2011 Jun; 93(6):750-759. PubMed ID: 21607655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXC chemokine receptor 4 expression, CXC chemokine receptor 4 activation, and wild-type nucleophosmin are independently associated with unfavorable prognosis in patients with acute myeloid leukemia.
    Konoplev S; Lin P; Yin CC; Lin E; Nogueras González GM; Kantarjian HM; Andreeff M; Medeiros LJ; Konopleva M
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):686-92. PubMed ID: 24035716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies.
    Peled A; Klein S; Beider K; Burger JA; Abraham M
    Cytokine; 2018 Sep; 109():11-16. PubMed ID: 29903571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TGF-β1 and CXCL12 modulate proliferation and chemotherapy sensitivity of acute myeloid leukemia cells co-cultured with multipotent mesenchymal stromal cells.
    Schelker RC; Iberl S; Müller G; Hart C; Herr W; Grassinger J
    Hematology; 2018 Jul; 23(6):337-345. PubMed ID: 29140182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia.
    Möhle R; Schittenhelm M; Failenschmid C; Bautz F; Kratz-Albers K; Serve H; Brugger W; Kanz L
    Br J Haematol; 2000 Sep; 110(3):563-72. PubMed ID: 10997965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside.
    Cho BS; Kim HJ; Konopleva M
    Korean J Intern Med; 2017 Mar; 32(2):248-257. PubMed ID: 28219003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Level of SDF-1/CXCR4 in children with acute leukemia and its significance].
    Wen Q; Chen RL; Cai KR; Lin YW
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):324-6. PubMed ID: 21518481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXCR4 is a prognostic marker in acute myelogenous leukemia.
    Spoo AC; Lübbert M; Wierda WG; Burger JA
    Blood; 2007 Jan; 109(2):786-91. PubMed ID: 16888090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype.
    Konoplev S; Rassidakis GZ; Estey E; Kantarjian H; Liakou CI; Huang X; Xiao L; Andreeff M; Konopleva M; Medeiros LJ
    Cancer; 2007 Mar; 109(6):1152-6. PubMed ID: 17315232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional CXCR4-expressing microparticles and SDF-1 correlate with circulating acute myelogenous leukemia cells.
    Kalinkovich A; Tavor S; Avigdor A; Kahn J; Brill A; Petit I; Goichberg P; Tesio M; Netzer N; Naparstek E; Hardan I; Nagler A; Resnick I; Tsimanis A; Lapidot T
    Cancer Res; 2006 Nov; 66(22):11013-20. PubMed ID: 17108140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice.
    Tavor S; Petit I; Porozov S; Avigdor A; Dar A; Leider-Trejo L; Shemtov N; Deutsch V; Naparstek E; Nagler A; Lapidot T
    Cancer Res; 2004 Apr; 64(8):2817-24. PubMed ID: 15087398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting CXCR4/SDF-1 axis by lipopolymer complexes of siRNA in acute myeloid leukemia.
    Landry B; Gül-Uludağ H; Plianwong S; Kucharski C; Zak Z; Parmar MB; Kutsch O; Jiang H; Brandwein J; Uludağ H
    J Control Release; 2016 Feb; 224():8-21. PubMed ID: 26742943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VLA-4 and CXCR4 expression levels show contrasting prognostic impact (favorable and unfavorable, respectively) in acute myeloid leukemia.
    Bae MH; Oh SH; Park CJ; Lee BR; Kim YJ; Cho YU; Jang S; Lee JH; Kim N; Park SH; Lim JH; Seo EJ; Lee KH
    Ann Hematol; 2015 Oct; 94(10):1631-8. PubMed ID: 26155911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCR4 Overexpression is a Poor Prognostic Factor in Pediatric Acute Myeloid Leukemia With Low Risk: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group.
    Matsuo H; Nakamura N; Tomizawa D; Saito AM; Kiyokawa N; Horibe K; Nishinaka-Arai Y; Tokumasu M; Itoh H; Kamikubo Y; Nakayama H; Kinoshita A; Taga T; Tawa A; Taki T; Tanaka S; Adachi S
    Pediatr Blood Cancer; 2016 Aug; 63(8):1394-9. PubMed ID: 27135782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.